Skip to Main Content

Paper Details

Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity.
Molecular Cancer Therapeutics
5
2021
CT26 tumors, GM-CSF, MEDI5395, NDV, NDVhuGM, NDVhuGM-CSF, NDVmuGM, NDVmuGM-CSF, Newcastle Disease, Newcastle Disease Virus, PD-L1, T-cell receptor, anti-PD-1, cancer, genes, human, human tumor cells, murine, murine tumor lines, transgene, tumor

Datasets

Release 1.2